TY - JOUR
T1 - Risk of secondary progressive multiple sclerosis after early worsening of disability
AU - Dzau, Winston
AU - Sharmin, Sifat
AU - Patti, Francesco
AU - Izquierdo, Guillermo
AU - Eichau, Sara
AU - Prat, Alexandre
AU - Girard, Marc
AU - Duquette, Pierre
AU - Onofrj, Marco
AU - Lugaresi, Alessandra
AU - Ozakbas, Serkan
AU - Gerlach, Oliver
AU - Boz, Cavit
AU - Grammond, Pierre
AU - Terzi, Murat
AU - Amato, Maria Pia
AU - La Spitaleri, Daniele
AU - Ramo-Tello, Cristina
AU - Maimone, Davide
AU - Cartechini, Elisabetta
AU - Buzzard, Katherine
AU - Skibina, Olga
AU - Van Der Walt, Anneke
AU - Butzkueven, Helmut
AU - Iuliano, Gerardo
AU - Soysal, Aysun
AU - Kalincik, Tomas
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023/12
Y1 - 2023/12
N2 - Background: Whether progression independent of relapse activity (PIRA) heralds earlier onset of secondary progressive multiple sclerosis (SPMS) and more rapid accumulation of disability during SPMS remains to be determined. We investigated the association between early PIRA, relapse-associated worsening (RAW) of disability and time to SPMS, subsequent disability progression and their response to therapy. Methods: This observational cohort study included patients with relapsing-remitting multiple sclerosis (RRMS) from the MSBase international registry across 146 centres and 39 countries. Associations between the number of PIRA and RAW during early multiple sclerosis (MS) (the initial 5 years of MS onset) were analysed with respect to: time to SPMS using Cox proportional hazards models adjusted for disease characteristics; and disability progression during SPMS, calculated as the change of Multiple Sclerosis Severity Scores over time, using multivariable linear regression. Results: 10 692 patients met the inclusion criteria: 3125 (29%) were men and the mean MS onset age was 32.2 years. A higher number of early PIRA (HR=1.50, 95% CI 1.28 to 1.76, p<0.001) and RAW (HR=2.53, 95% CI 2.25 to 2.85, p<0.001) signalled a higher risk of SPMS. A higher proportion of early disease-modifying therapy exposure (per 10%) reduced the effect of early RAW (HR=0.94, 95% CI 0.89 to 1.00, p=0.041) but not PIRA (HR=0.97, 95% CI 0.91 to 1.05, p=0.49) on SPMS risk. No association between early PIRA/RAW and disability progression during SPMS was found. Conclusions: Early disability increase during RRMS is associated with a greater risk of SPMS but not the rate of disability progression during SPMS. The deterioration associated with early relapses represents a potentially treatable risk factor of SPMS. Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12605000455662).
AB - Background: Whether progression independent of relapse activity (PIRA) heralds earlier onset of secondary progressive multiple sclerosis (SPMS) and more rapid accumulation of disability during SPMS remains to be determined. We investigated the association between early PIRA, relapse-associated worsening (RAW) of disability and time to SPMS, subsequent disability progression and their response to therapy. Methods: This observational cohort study included patients with relapsing-remitting multiple sclerosis (RRMS) from the MSBase international registry across 146 centres and 39 countries. Associations between the number of PIRA and RAW during early multiple sclerosis (MS) (the initial 5 years of MS onset) were analysed with respect to: time to SPMS using Cox proportional hazards models adjusted for disease characteristics; and disability progression during SPMS, calculated as the change of Multiple Sclerosis Severity Scores over time, using multivariable linear regression. Results: 10 692 patients met the inclusion criteria: 3125 (29%) were men and the mean MS onset age was 32.2 years. A higher number of early PIRA (HR=1.50, 95% CI 1.28 to 1.76, p<0.001) and RAW (HR=2.53, 95% CI 2.25 to 2.85, p<0.001) signalled a higher risk of SPMS. A higher proportion of early disease-modifying therapy exposure (per 10%) reduced the effect of early RAW (HR=0.94, 95% CI 0.89 to 1.00, p=0.041) but not PIRA (HR=0.97, 95% CI 0.91 to 1.05, p=0.49) on SPMS risk. No association between early PIRA/RAW and disability progression during SPMS was found. Conclusions: Early disability increase during RRMS is associated with a greater risk of SPMS but not the rate of disability progression during SPMS. The deterioration associated with early relapses represents a potentially treatable risk factor of SPMS. Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12605000455662).
KW - MULTIPLE SCLEROSIS
UR - http://www.scopus.com/inward/record.url?scp=85166407723&partnerID=8YFLogxK
U2 - 10.1136/jnnp-2023-331748
DO - 10.1136/jnnp-2023-331748
M3 - Article
C2 - 37414538
AN - SCOPUS:85166407723
SN - 0022-3050
VL - 94
SP - 984
EP - 991
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
IS - 12
M1 - 331748
ER -